GHSI logo

Guardion Health Sciences, Inc. (GHSI) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

GHSI representa a Guardion Health Sciences, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 46/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 46/100

Guardion Health Sciences, Inc. (GHSI) Resumen de Asistencia Médica y Tuberías

CEOMark Goldstone
Empleados9
Sede CentralSan Diego, US
Año de la oferta pública inicial (OPI)2019

Guardion Health Sciences, Inc. develops and markets medical foods, nutraceuticals, and medical devices targeting vision health. The company's focus on macular pigment and optic nerve support differentiates it within the specialty healthcare sector, addressing specific needs in ophthalmology with products like Lumega-Z and GlaucoCetin.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

Guardion Health Sciences operates in the niche market of vision-related medical foods, nutraceuticals, and devices. The company's focus on macular degeneration and glaucoma provides a targeted approach to address prevalent eye conditions. With a gross margin of 44.0%, GHSI demonstrates the potential for profitability as it scales its operations. Key growth catalysts include expanding the market reach of Lumega-Z and GlaucoCetin, as well as increasing adoption of its VectorVision line of medical devices. The company's online distribution channel through guardionhealth.com offers a direct-to-consumer approach, potentially improving margins and customer engagement. However, the company's small market capitalization and OTC listing present liquidity and regulatory risks. The P/E ratio of 26.14 suggests investors anticipate future earnings growth, but this also implies a higher valuation that needs to be justified by strong execution.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Guardion Health Sciences operates in two segments: Medical Foods and Nutraceuticals, and Medical Devices, diversifying its revenue streams within the vision health market.
  • The company offers Lumega-Z, a medical food designed to replenish and restore macular protective pigment, addressing a critical need in age-related macular degeneration.
  • GlaucoCetin, a vision-specific medical food, supports and protects the mitochondrial function of optic nerve cells, targeting glaucoma patients.
  • Guardion's VectorVision line includes devices like MapcatSF, CSV-1000, and CSV-2000, providing standardized vision testing solutions for eye doctors.
  • The company distributes its products through e-commerce via guardionhealth.com, enabling direct-to-consumer sales and broader market access.

Competidores y Pares

Fortalezas

  • Specialized product portfolio targeting vision health.
  • Proprietary formulations for medical foods.
  • Direct-to-consumer distribution channel.
  • Established brand recognition in the vision care market.

Debilidades

  • Small market capitalization.
  • Limited financial resources.
  • Dependence on a small number of key products.
  • OTC listing presents liquidity and regulatory risks.

Catalizadores

  • Ongoing: Expansion of Lumega-Z market reach through targeted marketing campaigns and partnerships with eye care professionals.
  • Ongoing: Increased adoption of VectorVision devices in clinical trials, real-world vision evaluation, and industrial vision testing.
  • Ongoing: Development and commercialization of ImmuneSF through existing e-commerce platform.
  • Upcoming: Potential strategic partnerships and acquisitions to expand product portfolio and market reach.
  • Upcoming: Positive clinical trial results demonstrating the efficacy of Lumega-Z or GlaucoCetin.

Riesgos

  • Potential: Competition from larger pharmaceutical and medical device companies with greater resources.
  • Potential: Regulatory changes affecting the medical food and nutraceutical industries.
  • Potential: Product liability claims related to the safety or efficacy of Guardion's products.
  • Ongoing: Economic downturn affecting consumer spending on healthcare products.
  • Ongoing: Risks associated with operating as an OTC-listed company, including limited liquidity and regulatory oversight.

Oportunidades de crecimiento

  • Expansion of Lumega-Z Market Reach: Lumega-Z, a medical food designed to replenish and restore the macular protective pigment, has a significant growth opportunity within the aging population. The global market for AMD treatment is projected to reach billions of dollars. By increasing awareness and distribution of Lumega-Z through targeted marketing campaigns and partnerships with eye care professionals, Guardion can capture a larger share of this growing market. Timeline: Ongoing.
  • Increased Adoption of VectorVision Devices: The VectorVision line of medical devices, including MapcatSF, CSV-1000, and CSV-2000, offers standardized vision testing solutions for eye doctors. By expanding the sales and marketing efforts for these devices, Guardion can increase their adoption in clinical trials, real-world vision evaluation, and industrial vision testing. The market for vision testing equipment is expected to grow. Timeline: Ongoing.
  • Development and Commercialization of ImmuneSF: ImmuneSF, a nutraceutical formulation, represents a growth opportunity for Guardion in the broader health and wellness market. By leveraging its expertise in formulation and distribution, Guardion can commercialize ImmuneSF through its existing e-commerce platform and expand its product portfolio. The nutraceuticals market is expected to continue its growth trajectory. Timeline: Ongoing.
  • Geographic Expansion: Guardion Health Sciences currently focuses on the United States market. Expanding its operations to international markets, such as Europe and Asia, represents a significant growth opportunity. By adapting its products and marketing strategies to local regulations and consumer preferences, Guardion can tap into new revenue streams and diversify its geographic footprint. Timeline: 2-3 years.
  • Strategic Partnerships and Acquisitions: Guardion can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with other companies in the vision care industry or acquiring complementary businesses can accelerate Guardion's growth and strengthen its competitive position. Timeline: Ongoing.

Oportunidades

  • Expansion of Lumega-Z market reach.
  • Increased adoption of VectorVision devices.
  • Development and commercialization of new products.
  • Geographic expansion into international markets.

Amenazas

  • Competition from larger pharmaceutical and medical device companies.
  • Regulatory changes affecting the medical food and nutraceutical industries.
  • Product liability claims.
  • Economic downturn affecting consumer spending on healthcare products.

Ventajas competitivas

  • Specialized product portfolio focused on vision health.
  • Proprietary formulations for medical foods like Lumega-Z and GlaucoCetin.
  • Established brand recognition in the vision care market.
  • Direct-to-consumer distribution channel through guardionhealth.com.

Acerca de GHSI

Guardion Health Sciences, Inc., founded in 2009 and headquartered in San Diego, California, is a specialty health sciences company dedicated to developing and commercializing innovative products for vision health. The company operates through two segments: Medical Foods and Nutraceuticals, and Medical Devices. Its flagship product, Lumega-Z, is a medical food designed to replenish and restore macular protective pigment, crucial for maintaining healthy vision. GlaucoCetin is another key product, a vision-specific medical food formulated to support and protect the mitochondrial function of optic nerve cells and improve blood flow in the ophthalmic artery for patients with glaucoma. In addition to medical foods, Guardion Health Sciences offers a range of medical devices. These include MapcatSF, which measures macular pigment optical density, and the CSV-1000 and CSV-2000 devices, standardized contrast sensitivity testing tools used by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. These devices are marketed under the VectorVision name. The company also develops ImmuneSF, a nutraceutical formulation, and markets a portfolio of nutraceutical products under the NutriGuard brand. Guardion distributes its products through e-commerce via its online store, guardionhealth.com, expanding its reach to a broader customer base. Guardion Health Sciences aims to address unmet needs in the vision health market through science-backed products and technologies.

Qué hacen

  • Develops and markets Lumega-Z, a medical food for macular pigment replenishment.
  • Offers GlaucoCetin, a vision-specific medical food for optic nerve support in glaucoma patients.
  • Provides MapcatSF, a medical device measuring macular pigment optical density.
  • Manufactures and sells CSV-1000 and CSV-2000 devices for standardized contrast sensitivity testing.
  • Develops ImmuneSF, a nutraceutical formulation.
  • Markets a portfolio of nutraceutical products under the NutriGuard brand.
  • Distributes products through e-commerce via guardionhealth.com.

Modelo de Negocio

  • Develops and sells medical foods targeting specific vision conditions.
  • Manufactures and sells medical devices for vision testing and evaluation.
  • Markets and distributes nutraceutical products for overall health and wellness.
  • Generates revenue through direct-to-consumer sales via its online store, guardionhealth.com.

Contexto de la Industria

Guardion Health Sciences operates within the specialty drug and medical device industry, focusing on vision care. The market for age-related macular degeneration (AMD) and glaucoma treatments is substantial and growing, driven by an aging population and increased awareness of eye health. The competitive landscape includes both pharmaceutical giants and smaller, specialized companies. Guardion differentiates itself through its focus on medical foods and nutraceuticals, offering alternative or complementary approaches to traditional pharmaceutical interventions. The company's success depends on its ability to demonstrate the efficacy and safety of its products through clinical studies and real-world evidence.

Clientes Clave

  • Patients with age-related macular degeneration (AMD).
  • Patients with glaucoma.
  • Eye doctors and optometrists using vision testing devices.
  • Individuals seeking nutraceutical products for overall health and wellness.
Confianza de la IA: 71% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Guardion Health Sciences, Inc. (GHSI): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GHSI.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para GHSI.

MoonshotScore

46/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de GHSI en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Mark Goldstone

CEO

Mark Goldstone serves as the CEO of Guardion Health Sciences, Inc. His background includes experience in managing and growing healthcare companies, with a focus on strategic planning and execution. He has a track record of driving revenue growth and improving operational efficiency. His expertise spans various aspects of the healthcare industry, including product development, marketing, and sales. Goldstone's leadership is focused on expanding Guardion's market presence and delivering innovative solutions for vision health.

Historial: Under Mark Goldstone's leadership, Guardion Health Sciences has focused on expanding its product portfolio and strengthening its distribution channels. Key achievements include the continued development and commercialization of Lumega-Z and GlaucoCetin, as well as the expansion of the VectorVision line of medical devices. Goldstone has also overseen the company's efforts to enhance its e-commerce platform and increase direct-to-consumer sales.

Información del mercado OTC de GHSI

The OTC Other tier represents the lowest tier of the OTC market, indicating that Guardion Health Sciences may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be subject to the same level of scrutiny. This can result in increased risks for investors due to the potential for fraud, lack of transparency, and limited liquidity.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: As an OTC Other stock, GHSI likely experiences low trading volume and wide bid-ask spreads. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The limited liquidity increases the risk of price volatility and makes it challenging to establish or exit positions quickly. Investors should be prepared for potential delays in order execution and the possibility of incurring higher transaction costs.
Factores de riesgo OTC:
  • Limited financial disclosure and transparency.
  • Potential for fraud and manipulation.
  • Low trading volume and liquidity.
  • Higher price volatility.
  • Limited regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's registration and compliance status with regulatory agencies.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Monitor trading activity and price volatility.
  • Consult with a qualified financial advisor.
  • Understand the risks associated with investing in OTC stocks.
Señales de legitimidad:
  • Established product portfolio targeting vision health.
  • Direct-to-consumer distribution channel through guardionhealth.com.
  • Presence in the vision care market.
  • Focus on medical foods and nutraceuticals.

Lo Que los Inversores Preguntan Sobre Guardion Health Sciences, Inc. (GHSI)

¿Cuáles son los factores clave para evaluar GHSI?

Guardion Health Sciences, Inc. (GHSI) actualmente tiene una puntuación IA de 46/100, indicando puntuación baja. Fortaleza clave: Specialized product portfolio targeting vision health.. Riesgo principal a monitorear: Potential: Competition from larger pharmaceutical and medical device companies with greater resources.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de GHSI?

GHSI actualmente puntúa 46/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de GHSI?

Los precios de GHSI se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre GHSI?

La cobertura de analistas para GHSI incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en GHSI?

Las categorías de riesgo para GHSI incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from larger pharmaceutical and medical device companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de GHSI?

La relación P/E para GHSI compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está GHSI sobrevalorada o infravalorada?

Determinar si Guardion Health Sciences, Inc. (GHSI) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de GHSI?

Guardion Health Sciences, Inc. (GHSI) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available data as of March 17, 2026.
  • OTC market data may be limited and subject to inaccuracies.
Fuentes de datos

Popular Stocks